Literature DB >> 32794637

Development and validation of an immune prognostic signature for ovarian carcinoma.

Seema Khadirnaikar1,2, Pranjal Kumar1, Sudhanshu Kumar Shukla1.   

Abstract

BACKGROUND: Ovarian cancer (OC) causes a significant proportion of cancer-related deaths in women. Recently, immunotherapy has emerged as a substantial player in cancer treatment. Lymphocyte infiltration, an important indicator of immune activity and disease aggressiveness, can be identified by gene expression profiling of immune-related genes of tumours which may prove useful in prognosis of patients. AIMS: The aim of this study is to identify and validate a novel immune gene-based prognostic signature for OC. METHODS AND
RESULTS: Here, we extracted the expression of immune-related genes and performed the Cox regression analysis and identified five genes with significant correlation with survival in training cohort of patients (n = 286). We utilised regression coefficient and expression level of five genes to calculate immune prognostic signature (IPS) score for OC patients. In univariate and multivariate Cox regression analysis with other clinicopathological factors, we showed that IPS is an independent predictor of survival (P value <0.01). More importantly, we utilised 404 patients from TCGA dataset as the validation cohort and validated the survival capability of IPS in the univariate and multivariate analysis (P value <0.001). Interestingly, KM analysis showed a significant difference in survival of patients with high and low IPS score in both datasets (training dataset P value <0.01, validation dataset P value <0.01). Further, we showed that all the five genes are differentially expressed and involved in immune modulation among other pathways. Interestingly, GSEA analysis showed that high IPS patients had low immune activity and activated EMT and other oncogenic pathways.
CONCLUSION: In summary, we have developed and validated robust immune-related gene-based prognostic signature to identify the OC patients with high immune activity who can be taken for immunotherapy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  immune activity; immunotherapy; ovarian cancer; prognostic signature

Year:  2019        PMID: 32794637      PMCID: PMC7941549          DOI: 10.1002/cnr2.1166

Source DB:  PubMed          Journal:  Cancer Rep (Hoboken)        ISSN: 2573-8348


  32 in total

1.  Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma.

Authors:  R Oka; T Sasagawa; I Ninomiya; K Miwa; H Tanii; K Saijoh
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks.

Authors:  Cole Trapnell; Adam Roberts; Loyal Goff; Geo Pertea; Daehwan Kim; David R Kelley; Harold Pimentel; Steven L Salzberg; John L Rinn; Lior Pachter
Journal:  Nat Protoc       Date:  2012-03-01       Impact factor: 13.491

4.  Pleural Fluid Adenosine Deaminase (ADA) Predicts Survival in Patients with Malignant Pleural Effusion.

Authors:  Ricardo Mingarini Terra; Leila Antonangelo; Alessandro Wasum Mariani; Ricardo Lopes Moraes de Oliveira; Lisete Ribeiro Teixeira; Paulo Manuel Pego-Fernandes
Journal:  Lung       Date:  2016-06-14       Impact factor: 2.584

5.  Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population.

Authors:  Z Wang; J Liao; S Wu; C Li; J Fan; Z Peng
Journal:  Cancer Gene Ther       Date:  2016-05-13       Impact factor: 5.987

6.  Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.

Authors:  Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 8.  New perspectives on targeted therapy in ovarian cancer.

Authors:  Jermaine Ig Coward; Kathryn Middleton; Felicity Murphy
Journal:  Int J Womens Health       Date:  2015-02-04

Review 9.  Cancer immunotherapy: the beginning of the end of cancer?

Authors:  Sofia Farkona; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  BMC Med       Date:  2016-05-05       Impact factor: 8.775

10.  GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists.

Authors:  Eran Eden; Roy Navon; Israel Steinfeld; Doron Lipson; Zohar Yakhini
Journal:  BMC Bioinformatics       Date:  2009-02-03       Impact factor: 3.169

View more
  3 in total

1.  Development and validation of an immune prognostic signature for ovarian carcinoma.

Authors:  Seema Khadirnaikar; Pranjal Kumar; Sudhanshu Kumar Shukla
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-19

2.  Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer.

Authors:  Jiang Yang; Shasha Hong; Xiaoyi Zhang; Jingchun Liu; Ying Wang; Zhi Wang; Likun Gao; Li Hong
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

3.  Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer.

Authors:  Lingyun Zhang; Wenwen Sun; Weimin Ren; Jinguo Zhang; Guoxiong Xu
Journal:  Front Cell Dev Biol       Date:  2021-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.